Devonian preclinical data support Thykamine

Dr. Andre Boulet reports DEVONIAN REPORTS ADDITIONAL MOLECULAR DATA FROM MASH LIVER STUDY Devonian Health Group Inc. has released additional preclinical results from its previously reported STAM mouse model in vivo study of metabolic dysfunction-associated steatohepatitis. These new data provide gene expression evidence supporting the anti-MASH, anti-inflammatory and anti-fibrotic effects of Thykamine observed in the liver. As previously reported, the STAM mouse model study demonstrated that orally administered Thykamine, at doses of 0.5 milligram per kilogram, 5.0 mg/kg and 50.0 mg/kg once daily for three weeks, significantly reduced liver disease progression, inflammation and fibrosis. The gene expression results announced today further characterize the molecular mechanisms underlying these effects. The study evaluated the impact of Thykamine on the expression of 29 genes associated with liver fibrosis and inflammation, including 13 fibrosis-related genes, five inflammation-related genes, and 11 genes involved in both inflammation and fibrosis pathways. At the maximum tested dose, Thykamine treatment resulted in marked-down regulation of multiple genes central to MASH pathophysiology, with several demonstrating reductions approaching or exceeding 80 to 90 per cent relative to placebo-treated animals. Fibrosis-related genes significantly modulated by Thykamine included CCN1, CCN2, COL1A1, COL1A2, COL5A2, JAG1, MMP2, MMP13, Serpine1, Serpine2, SNAI1 and TGFBR1, supporting the previously observed decreases in collagen deposition, alpha-SMA expression and fibrosis progression. Thykamine treatment also resulted in significant down regulation of inflammation-related genes, including CCL2, CCR2, IFNG and MMO8, as well as genes involved in both inflammatory and fibrotic remodelling such as COL3A1, COL6A1, FN1, TGFB1, TIMP1, MMP14, TNF, IL10 and TLR4. A dose-dependent response was observed across gene categories, consistent with a pharmacologically driven effect. In addition, gene expression analysis revealed key differences between the caudal and lateral liver lobes, indicating regional variation in Thykamine's molecular activity within the diseased liver. Gene expression analysis (PCR) was performed by Dr. Louis Flamand, PhD, MBA, department of microbiology, infectious disease and immunology, faculty of medicine, Universite Laval, Quebec City, Que., Canada. Statistical analyses were conducted by Dr. John Sampalis, PhD, department of surgery, McGill University, Montreal, Que., Canada. "We are delighted to share these gene expression results, which provide important molecular confirmation of the anti-inflammatory and anti-fibrotic effects of Thykamine observed in the STAM MASH model," said Dr. Andre P. Boulet, PhD, chief executive officer of the company. "The data demonstrate that Thykamine modulates multiple genes involved in fibrosis and inflammation, reinforcing its potential to target underlying disease pathology and prevent progression of MASH. "This study further adds to the growing body of evidence supporting Thykamine's multitargeting mode of action," said Dr. Boulet. "By demonstrating consistent effects at both the histological and molecular levels, these results strengthen Thykamine's positioning across a broad array of inflammatory diseases, now including hepatic conditions alongside dermatology and inflammatory bowel disease." The complete gene expression results will be included in the planned scientific publication of the STAM MASH preclinical study. About Devonian Health Group Inc. Devonian is a clinical-stage pharmaceutical company specializing in the development of drugs for various auto-immune fibroinflammatory conditions with novel therapeutic approaches to targeting unmet medical needs. Devonian's core strategy is to develop prescription drugs for the treatment of inflammatory autoimmune diseases, including, but not limited to, ulcerative colitis and atopic dermatitis. Based on a foundation of over 15 years of research, Devonian's focus is further supported by a U.S. Food and Drug Administration set of regulatory guidelines favouring a more efficient drug development pathway for prescription botanical drug products over those of traditional prescription medicines. Devonian is also involved in the development of high-value cosmeceutical products leveraging the same proprietary approach employed with their pharmaceutical offerings. Devonian also owns a commercialization subsidiary, Altius Healthcare LP, focused on selling prescription pharmaceutical products in Canada, under licence from brand name pharmaceutical companies. Devonian was incorporated in 2015 and is headquartered in Quebec, Canada, where it owns a state-of-the art extraction facility. Devonian is traded publicly on the TSX Venture Exchange and on the OTCQB exchange. We seek Safe Harbor.